Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Journal of clinical oncology

Results: 1-25/599

Authors: Jordan, VC
Citation: Vc. Jordan, Tamoxifen: Too much of a good thing?, J CL ONCOL, 17(9), 1999, pp. 2629-2630

Authors: Laufer, MR
Citation: Mr. Laufer, Reproductive issues for cancer patients/survivors, J CL ONCOL, 17(9), 1999, pp. 2631-2632

Authors: Decensi, A Gandini, S Guerrieri-Gonzaga, A Johansson, H Manetti, L Bonanni, B Sandri, MT Barreca, A Costa, A Robertson, C Lien, EA
Citation: A. Decensi et al., Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women, J CL ONCOL, 17(9), 1999, pp. 2633-2638

Authors: Cobleigh, MA Vogel, CL Tripathy, D Robert, NJ Scholl, S Fehrenbacher, L Wolter, JM Paton, V Shak, S Lieberman, G Slamon, DJ
Citation: Ma. Cobleigh et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J CL ONCOL, 17(9), 1999, pp. 2639-2648

Authors: Thames, HD Buchholz, TA Smith, CD
Citation: Hd. Thames et al., Frequency of first metastatic events in breast cancer: Implications for sequencing of systemic and local-regional treatment, J CL ONCOL, 17(9), 1999, pp. 2649-2658

Authors: Day, R Ganz, PA Costantino, JP Cronin, WM Wickerham, DL Fisher, B
Citation: R. Day et al., Health-related quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 study, J CL ONCOL, 17(9), 1999, pp. 2659-2669

Authors: Brewer, M Gershenson, DM Herzog, CE Mitchell, MF Silva, EG Wharton, JT
Citation: M. Brewer et al., Outcome and reproductive function after chemotherapy for ovarian dysgerminoma, J CL ONCOL, 17(9), 1999, pp. 2670-2675

Authors: Rose, PG Blessing, JA Gershenson, DM McGehee, R
Citation: Pg. Rose et al., Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study, J CL ONCOL, 17(9), 1999, pp. 2676-2680

Authors: Bonner, JA Sloan, JA Shanahan, TG Brooks, BJ Marks, RS Krook, JE Gerstner, JB Maksymiuk, A Levitt, R Mailliard, JA Tazelaar, HD Hillman, S Jett, JR
Citation: Ja. Bonner et al., Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma, J CL ONCOL, 17(9), 1999, pp. 2681-2691

Authors: Furuse, K Fukuoka, M Kawahara, M Nishikawa, H Takada, Y Kudoh, S Katagami, N Ariyoshi, Y
Citation: K. Furuse et al., Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer, J CL ONCOL, 17(9), 1999, pp. 2692-2699

Authors: Stuschke, M Eberhardt, W Pottgen, C Stamatis, G Wilke, H Stuben, G Stoblen, F Wilhelm, HH Menker, H Teschler, H Muller, RD Budach, V Seeber, S Sack, H
Citation: M. Stuschke et al., Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigationsof late neuropsychologic effects, J CL ONCOL, 17(9), 1999, pp. 2700-2709

Authors: DeVore, RF Johnson, DH Crawford, J Garst, J Dimery, IW Eckardt, J Eckhardt, SG Elfring, GL Schaaf, LJ Hanover, CK Miller, LL
Citation: Rf. Devore et al., Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer, J CL ONCOL, 17(9), 1999, pp. 2710-2720

Authors: Sato, G Saijo, Y Uchiyama, B Kumano, N Sugawara, S Fujimura, S Sato, M Sagawa, M Ohkuda, K Koike, K Minami, Y Satoh, K Nukiwa, T
Citation: G. Sato et al., Prognostic value of nucleolar protein p120 in patients with resected lung adenocarcinoma, J CL ONCOL, 17(9), 1999, pp. 2721-2727

Authors: Tanaka, F Kawano, Y Li, M Takata, T Miyahara, R Yanagihara, K Ohtake, Y Fukuse, T Wada, H
Citation: F. Tanaka et al., Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer, J CL ONCOL, 17(9), 1999, pp. 2728-2736

Authors: Highley, MS Underhill, CR Parnis, FX Karapetis, C Rankin, E Dussek, J Bryant, B Rowland, C Hodson, N Hughes, J Harper, PG
Citation: Ms. Highley et al., Treatment of invasive thymoma with single-agent ifosfamide, J CL ONCOL, 17(9), 1999, pp. 2737-2744

Authors: Chapman, PB Einhorn, LH Meyers, ML Saxman, S Destro, AN Panageas, KS Begg, CB Agarwala, SS Schuchter, LM Ernstoff, MS Houghton, AN Kirkwood, JM
Citation: Pb. Chapman et al., Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma, J CL ONCOL, 17(9), 1999, pp. 2745-2751

Authors: O'Day, SJ Gammon, G Boasberg, PD Martin, MA Kristedja, TS Guo, M Stern, S Edwards, S Fournier, P Weisberg, M Cannon, M Fawzy, NW Johnson, TD Essner, R Foshag, LJ Morton, DL
Citation: Sj. O'Day et al., Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma, J CL ONCOL, 17(9), 1999, pp. 2752-2761

Authors: Yung, WKA Prados, MD Yaya-Tur, R Rosenfeld, SS Brada, M Friedman, HS Albright, R Olson, J Chang, SM O'Neill, AM Friedman, AH Bruner, J Yue, N Dugan, M Zaknoen, S Levin, VA
Citation: Wka. Yung et al., Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse, J CL ONCOL, 17(9), 1999, pp. 2762-2771

Authors: Fleming, JB Berman, RS Cheng, SC Chen, NP Hunt, KK Feig, BW Respondek, PM Yasko, AW Pollack, A Patel, SR Burgess, MA Papadopoulos, NE Plager, C Zagars, G Benjamin, RS Pollock, RE Pisters, PWT
Citation: Jb. Fleming et al., Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas, J CL ONCOL, 17(9), 1999, pp. 2772-2780

Authors: Gorlick, R Huvos, AG Heller, G Aledo, A Beardsley, GP Healey, JH Meyers, PA
Citation: R. Gorlick et al., Expression of HER2/erbB-2 correlates with survival in osteosarcoma, J CL ONCOL, 17(9), 1999, pp. 2781-2788

Authors: Tabone, MD Terrier, P Pacquement, H Brunat-Mentigny, M Schmitt, C Babin-Boilletot, A Mahmoud, HH Kalifa, C
Citation: Md. Tabone et al., Outcome of radiation-related osteosarcoma after treatment of childhood andadolescent cancer: A study of 23 cases, J CL ONCOL, 17(9), 1999, pp. 2789-2795

Authors: Carli, M Colombatti, R Oberlin, O Stevens, M Masiero, L Frascella, E Koscielniak, E Treuner, J Pinkerton, CR
Citation: M. Carli et al., High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma, J CL ONCOL, 17(9), 1999, pp. 2796-2803

Authors: Vera, P Rohrlich, P Stievenart, JL Elmaleh, M Duval, M Bonnin, F Bok, B Vilmer, E
Citation: P. Vera et al., Contribution of single-photon emission computed tomography in the diagnosis and follow-un of CNS toxicity of a cytarabine-containing regimen in pediatric leukemia, J CL ONCOL, 17(9), 1999, pp. 2804-2810

Authors: Rizzo, JD Vogelsang, GB Krumm, S Frink, B Mock, V Bass, EB
Citation: Jd. Rizzo et al., Outpatient-based bone marrow transplantation for hematologic malignancies:Cost saving or cost shifting?, J CL ONCOL, 17(9), 1999, pp. 2811-2818

Authors: Beran, M Estey, E O'Brien, S Cortes, J Koller, CA Giles, FJ Kornblau, S Andreeff, M Vey, N Pierce, SR Hayes, K Wong, GC Keating, M Kantarjian, H
Citation: M. Beran et al., Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia, J CL ONCOL, 17(9), 1999, pp. 2819-2830
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>